Navigation Links
Another JDRF partner moves research forward with collaboration agreement for diabetes treatment
Date:6/18/2009

NEW YORK, June 18, 2009 The Juvenile Diabetes Research Foundation said today that for the fourth time in 18 months, one of its biotech partners has signed a collaboration agreement with a large pharmaceutical company to move research on type 1 diabetes into the final phases of trials.

According to JDRF, a leader in setting the agenda for diabetes research worldwide and the largest charitable funder and advocate of type 1 diabetes research, the development is the latest success in its innovative Industry Discovery and Development Partnership (IDDP) program, through which JDRF provides early stage research funding to biotech companies working on technologies and therapeutic candidates.

In the most recent success, JDRF industry partner Bayhill Therapeutics Inc., based in California, entered into a collaboration agreement with Genentech, Inc., a wholly owned member of the Roche Group, to further develop and potentially commercialize a novel antigen-specific immunotherapeutic designed to reverse the immune response that causes type 1 diabetes.

To date, JDRF has awarded more than $29 million in research funding to 25 companies through its IDDP program. JDRF supported the ongoing Bayhill clinical trial with an IDDP grant in October of 2008.

"We began the IDDP program to help small companies demonstrate proof-of-principle for innovative ideas and products to treat and cure type 1 diabetes, in order to attract funding for potential commercialization from large drug companies," said Alan J. Lewis, PhD, President and Chief Executive Officer of JDRF. "This latest agreement further demonstrates that the strategy is successful in accelerating the pace of research leading to a cure for diabetes."

Dr. Lewis noted that the development underscores JDRF's unique role helping to accelerate and translate research discoveries into cures and better treatment of type 1 diabetes and its complications. By supporting early stage research at small biotech companies, JDRF looks to lower the risk for larger pharmaceutical companies to create biotech partnerships and carry the products through expensive, late-stage trials and regulatory approvals. The goal, he said, is to bring cures and treatments for type 1 diabetes to market faster.

Other IDDP partners that have created similar agreements include: Tolerx, based in Massachusetts, which has joined with GlaxoSmithKline to develop an anti-CD3 antibody to preserve beta cell function in newly diagnosed patients; Maryland-based MacroGenics, which is developing a similar antibody with Lilly; and Canada's Transition Therapeutics, which has signed a commercialization agreement for a beta cell regenerative therapy with Lilly.

Bayhill's BHT-3021 compound is now in Phase I/II clinical trials supported by JDRF, is a plasmid encoding proinsulin designed to target specific pathogenic immune cells involved in the immune response of type 1 diabetes.


'/>"/>

Contact: William Ahearn
wahearn@jdrf.org
212-479-7531
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. One species entire genome discovered inside anothers
2. Same gene protects from 1 disease, opens door to another
3. Another type of nanotube, a how-to guide to making bamboo-structured carbon nanotubes
4. For good or ill Ireland gains another mammal species
5. Ocean acidification -- another undesired side effect of fossil fuel-burning
6. Viral recombination another way HIV fools the immune system
7. Arctic ice on the verge of another all-time low
8. Another fisheries commission throws the science overboard in tuna decision, WWF says
9. Another reason to drink a nice cup of shade-grown joe
10. Cancer: Another step towards medication
11. Desert woodrats switch one dietary poison for another
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Vice President of Clinical Operations. She brings years of expertise in establishing and ... her professional foundation as a licensed occupational therapist, through a variety of leadership ...
(Date:5/22/2017)... , ... May 22, 2017 , ... ... with other leaders of the Maryland Biohealth community in developing and issuing recommendations ... Top 3 U.S. BioHealth Innovation Hub by 2023. , The ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... Program. Academic researchers with technologies ripe for commercialization, and who are affiliated ... Delaware, are encouraged to submit proposals. QED, now in its tenth round, is ...
Breaking Biology Technology: